Dissection of cancer therapy combinations in RTK driven tumors using zotatifin (eFT226), a potent and selective eIF4A inhibitor. (October 2020) - Gerson-Gurwitz, A.; Goel, V.K.; Young, N.P.; Eam, B.; Stumpf, C.R.; Barrera, M.; Sung, E.; Staunton, J.; Chen, J.; Fish, S.; Chiang, G.G.; Thompson, P.A.